Skip to main
HROW
HROW logo

HROW Stock Forecast & Price Target

HROW Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harrow Inc. exhibits a strong growth trajectory, highlighted by a 22% quarter-over-quarter revenue increase for its flagship product VEVYE, reaching $22.6 million in the third quarter of 2025. The company has secured a 10.5% share of the national dry eye disease market, showcasing its competitive positioning and potential for further gains, supported by ongoing prescription growth momentum. Anticipations of a quarterly revenue run rate surpassing $250 million by the fourth quarter of 2027, which would represent a significant increase compared to prior results, enhance confidence in Harrow's strategic direction and long-term margin expansion potential.

Bears say

Harrow Inc faces significant risk factors that contribute to a negative outlook on its stock, primarily centered around the potential for unfavorable clinical data and regulatory approval for products developed by its spinouts, which could diminish product opportunities and adversely impact the company’s valuation. Additionally, the company may experience lower-than-expected market uptake for its products and faces challenges in developing its pipeline, acquiring new products, and servicing its existing debt, all of which could materially affect its financial stability. Furthermore, as a small company with limited resources, Harrow Inc may be compelled to scale back on sales and marketing efforts and could require capital raises that would lead to further dilution of existing shareholders.

HROW has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harrow Health Inc (HROW) Forecast

Analysts have given HROW a Strong Buy based on their latest research and market trends.

According to 7 analysts, HROW has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harrow Health Inc (HROW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.